Comparative Pharmacology
Head-to-head clinical analysis: ORAQIX versus PHISOHEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORAQIX versus PHISOHEX.
ORAQIX vs PHISOHEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oraqix is a eutectic mixture of lidocaine and prilocaine that acts as a local anesthetic. It reversibly blocks sodium ion channels in nerve cell membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing anesthesia.
Disrupts bacterial cell wall synthesis by binding to the bacterial ribosome and inhibiting protein synthesis; also has surfactant properties that disrupt bacterial cell membrane integrity.
750 mg orally once daily for 5 days; or 250 mg orally once daily for 5 days (levofloxacin equivalent).
Apply topically as a 3% emulsion to affected area, rinse thoroughly; typically used 1-2 times daily for up to 10 days.
None Documented
None Documented
Terminal elimination half-life: 7.5 hours (range 6-9 h) in patients with normal renal function; extends to 20-30 h in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal elimination half-life approximately 6-7 hours in adults with normal renal function. Prolonged in renal impairment (up to 20 hours) due to reduced clearance of active metabolite (pentachlorophenol).
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites and parent drug; total clearance approximates renal clearance.
Renal (biliary/fecal negligible). Up to 10% of dose excreted unchanged in urine; remainder as metabolites (glucuronide and sulfate conjugates).
Category C
Category C
Antiseptic
Antiseptic